AR overexpression
|
Triple Negative Breast Cancer
|
AR overexpression
|
Triple Negative Breast Cancer
|
TAK 700 Sensitive: C3 – Early Trials
|
TAK 700 Sensitive: C3 – Early Trials
|
AR overexpression
|
Prostate Cancer
|
AR overexpression
|
Prostate Cancer
|
enzalutamide capsule Sensitive: C3 – Early Trials
|
enzalutamide capsule Sensitive: C3 – Early Trials
|
AR overexpression
|
Triple Negative Breast Cancer
|
AR overexpression
|
Triple Negative Breast Cancer
|
enzalutamide capsule Sensitive: C3 – Early Trials
|
enzalutamide capsule Sensitive: C3 – Early Trials
|
AR overexpression
|
Breast Cancer
|
AR overexpression
|
Breast Cancer
|
paclitaxel Sensitive: C3 – Early Trials
|
paclitaxel Sensitive: C3 – Early Trials
|
AR overexpression
|
HER2 Positive Breast Cancer
|
AR overexpression
|
HER2 Positive Breast Cancer
|
TCHP Sensitive: C3 – Early Trials
|
TCHP Sensitive: C3 – Early Trials
|
AR overexpression
|
Estrogen Receptor Positive Breast Cancer
|
AR overexpression
|
Estrogen Receptor Positive Breast Cancer
|
RAD140 Sensitive: D – Preclinical
|
RAD140 Sensitive: D – Preclinical
|
AR overexpression
|
Prostate Cancer
|
AR overexpression
|
Prostate Cancer
|
BMS-641988 Resistant: D – Preclinical
|
BMS-641988 Resistant: D – Preclinical
|